Hemodynamic changes caused by glibenclamide in isolated, working, erythrocyte perfused rat heart.

Abstract

Glibenclamide-induced cardiac hemodynamic changes before and after ischemia have been frequently studied. In general a Langendorff buffer perfused heart model was used to examine these effects. However these models used protein-free buffer perfusates. To improve clinical relevance and thereby enhance extrapolation to the in vivo condition we studied the effects of glibenclamide on cardiac hemodynamics using a working, erythrocyte perfused, rat heart model, where the perfusate was enriched with albumin. The results show a dose-dependent decline in CBF in normoxia and at the end of reperfusion (after an ischemic period) with glibenclamide treatment compared to control. Cardiac functional recovery improved with 1 and 4 mumol.L-1 glibenclamide concentrations. From this study it seems that there is a marked decrease in CBF but this did not result in impaired myocardial function after a period of ischemia, so it appears that there are no startling side effects of glibenclamide in the ischemic rat heart.

• Authors: R J Legtenberg, R J Houston, P Smits, B Oeseburg
• Journal: Advances in experimental medicine and biology (Adv Exp Med Biol) Vol. 471 Pg. 257-63 ( 1999) ISSN: 0065-2598 [Print] United States
• PMID: 10659155 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Hypoglycemic Agents
• Potassium Channel Blockers
• Glyburide

Topics

• Animals
• Coronary Vessels (drug effects, physiopathology)
• Erythrocytes
• Glyburide (pharmacology)
• Heart (drug effects, physiopathology)
• Hemodynamics (drug effects)
• Hypoglycemic Agents (pharmacology)
• Male
• Potassium Channel Blockers
• Rats
• Rats, Wistar